Inversine

(Mecamylamine)

ApprovedSmall molecule

TTargacept Inc.

Inversine is one of 222 small molecule programs targeting Autonomic Dysreflexia. It is currently in Approved.

Indications

Total Trials

Active Trials

221

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Autonomic DysreflexiaActive, not recruiting

Orthostatic IntoleranceActive, not recruiting

Alcohol DependenceActive, not recruiting

Autism Spectrum DisorderActive, not recruiting

Wet Age-Related Macular DegenerationActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Major Depressive DisorderActive, not recruiting

SchizophreniaActive, not recruiting

Smoking CessationActive, not recruiting

Autonomic DysreflexiaApproved

Active, not recruiting

Orthostatic IntolerancePhase 1/Phase 2

Active, not recruiting

Alcohol DependencePhase 3

Active, not recruiting

Autism Spectrum DisorderPhase 1

Active, not recruiting

Diabetic Macular EdemaPhase 2

Active, not recruiting

Major Depressive DisorderPhase 2

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

Smoking CessationPhase 1

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Inversine

TTargacept Inc.

Approved

1 2

Celexa

AbbVie

Preclinical

4 3

Resotran

Takeda

Preclinical

1 4

Depakote

Lunesta

3 6

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 7

Luvox

SSolvay Pharmaceuticals

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Compazine

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Active, not recruiting

Orthostatic Intolerance

NCT00262470

Clinical

Trials by Indication[1]

Treatment2 trials

Treatment to Quit Smoking

Completed·UUS Department of Veterans Affairs·Phase 2·NCT00018161

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Completed·YYale University·Phase 2·NCT00342563·136 enrolled

Smoking Cessation1 trial

Combinations of Pharmacologic Smoking Cessation Treatments

Completed·UUS Department of Veterans Affairs·Phase 1·NCT00018187

Autism Spectrum Disorder1 trial

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

Completed·OOhio State University·Phase 1·NCT00773812·20 enrolled

Orthostatic Intolerance1 trial

Treatment of Orthostatic Intolerance

Active, not recruiting·SSatish R. Raj·Phase 1/2·NCT00262470·150 enrolled

Diabetic Macular Edema1 trial

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

Completed·CCoMentis·Phase 2·NCT00536692

6 more indications

Alcohol Dependence1 trial

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Completed·YYale University·Phase 3·NCT00563797·21 enrolled

Schizophrenia1 trial

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

Completed·MMassachusetts General Hospital·N/A·NCT00455650·89 enrolled

Major Depressive Disorder1 trial

Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder

Completed·TTargacept Inc.·Phase 2·NCT00593879·450 enrolled

Wet Age-Related Macular Degeneration1 trial

Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

Terminated·CCoMentis·Phase 2·NCT00414206·343 enrolled

Autonomic Dysreflexia1 trial

Mecamylamine for Autonomic Dysreflexia Prophylaxis

Unknown status·WWayne State University·Phase 4·NCT03914677·5 enrolled

Unspecified1 trial

Nicotinic Modulation of the Default Network

Completed·UUniversity of Maryland, Baltimore·N/A·NCT01223404·21 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

INVERSINE

NDA NDA010251

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Mecamylamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mecamylamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mecamylamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA010251). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Targacept Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTargacept Inc.

Inversine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Treatment2 trials

Smoking Cessation1 trial

Autism Spectrum Disorder1 trial

Orthostatic Intolerance1 trial

Diabetic Macular Edema1 trial

Alcohol Dependence1 trial

Schizophrenia1 trial

Major Depressive Disorder1 trial

Wet Age-Related Macular Degeneration1 trial

Autonomic Dysreflexia1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News